Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO Update: Seven In January As Big Returns, Solid's Slip-Up Contribute To Bubble Concerns

Executive Summary

Seven biopharma IPOs launched in the US in January with an average return of 52.8%. The most recent was Sol-Gel's on Jan. 31, but the largest was a $128m offering by ARMO. Solid had the most controversial IPO, but it still gave investors a 70.7% return, contributing to the question: Is biotech in a bubble?

Advertisement

Related Content

IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose
Pipeline Watch: Phase III Starts For BL-8040, Trigriluzole, MIN-101
resTORbio's Age-Related RTI Program Picks Up Further Funding
IPO Update: New Filings Feed Investor Fervor As Biopharma Stocks Rise
Finance Watch: Lilly Cuts 3,500 Jobs Globally To Drive Growth
Finance Watch VC Edition: Biopharma Venture Investment Rises In Second Quarter
What Could Come After CAR-T? Cue Is Betting On Selective Biologics
Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda
ARMO Rides Immuno-Oncology Wave With $50m For Its PD-1 Booster
FINANCE ROUNDUP: A New VC Fund, A $60m Collaboration Boost, And 14 Funding Rounds

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100315

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel